HOWARD J. FEDEROFF

Corporate Board Profile

Tech Score: 0/100

Eterna Therapeutics Inc.

Filing Date	Source Excerpt
2021-07-01	Howard Federoff Age: 68 Board Service · Tenure: Since April 2021 · Chief Executive Officer and President since April 2021 INDEPENDENT
2022-04-26	Howard Federoff, M.D., Ph.D., has served as Chief Executive Officer, President and one of our directors since April 2021. Prior to that, Dr. Federoff served as senior adviser from January 2021 to April 2021 and as chief executive officer from August 2019 to December 2020 at Aspen Neuroscience, Inc., a biotechnology company developing an autologous neuron replacement program for Parkinson’s disease. He is a former Professor of Neurology at the University of California, Irvine, School of Medicine from 2015 to April 2021. Dr. Federoff also served as Vice Chancellor for Health Affairs and Chief Executive Officer of the UC Irvine Health System from 2016 to 2018 and as Vice Chancellor for Health Affairs and Interim Chief Executive Officer of the UC Irvine Health System and as Dean of the University of California, Irvine, School of Medicine from 2015 to 2016. From 2007 to 2015 he was Executive Vice President for Health Sciences and Executive Dean of the School of Medicine at Georgetown University. Dr. Federoff has chaired the Recombinant DNA Advisory Committee of the National Institute of Health, the National Heart, Lung and Blood Institute Gene Therapy Resource Group, and the Board of the Association of Academic Health Centers. Dr. Federoff is an elected Fellow of the American Association for the Advancement of Science and the National Academy of Investors. Dr. Federoff received a Ph.D. in Biochemistry and an M.D. from Albert Einstein College of Medicine of Yeshiva University. Dr. Federoff’s qualifications to serve on our Board of Directors include his experience in the healthcare industry, his business training and education, and his experience serving on multiple boards over the course of his career. 2021 Director Compensation: Not separately stated.

Filing Date

Source Excerpt

2021-07-01

Howard Federoff Age: 68 Board Service · Tenure: Since April 2021 · Chief Executive Officer and President since April 2021 INDEPENDENT

2022-04-26

Howard Federoff, M.D., Ph.D., has served as Chief Executive Officer, President and one of our directors since April 2021. Prior to that, Dr. Federoff served as senior adviser from January 2021 to April 2021 and as chief executive officer from August 2019 to December 2020 at Aspen Neuroscience, Inc., a biotechnology company developing an autologous neuron replacement program for Parkinson’s disease. He is a former Professor of Neurology at the University of California, Irvine, School of Medicine from 2015 to April 2021. Dr. Federoff also served as Vice Chancellor for Health Affairs and Chief Executive Officer of the UC Irvine Health System from 2016 to 2018 and as Vice Chancellor for Health Affairs and Interim Chief Executive Officer of the UC Irvine Health System and as Dean of the University of California, Irvine, School of Medicine from 2015 to 2016. From 2007 to 2015 he was Executive Vice President for Health Sciences and Executive Dean of the School of Medicine at Georgetown University. Dr. Federoff has chaired the Recombinant DNA Advisory Committee of the National Institute of Health, the National Heart, Lung and Blood Institute Gene Therapy Resource Group, and the Board of the Association of Academic Health Centers. Dr. Federoff is an elected Fellow of the American Association for the Advancement of Science and the National Academy of Investors. Dr. Federoff received a Ph.D. in Biochemistry and an M.D. from Albert Einstein College of Medicine of Yeshiva University. Dr. Federoff’s qualifications to serve on our Board of Directors include his experience in the healthcare industry, his business training and education, and his experience serving on multiple boards over the course of his career. 2021 Director Compensation: Not separately stated.

Data sourced from SEC filings. Last updated: 2025-08-30